Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5604]
News [13558]
Articles [218]
Editorials [5]
Conferences [266]
elearning [17]
Promising new option for skin cancer reconstruction
Promising new option for skin cancer reconstruction
WCLC 2026: Subcutaneous tarlatamab shows favourable safety profile and antitumour activity in extensive-stage small cell lung cancer
WCLC 2026: Subcutaneous tarlatamab shows favourable safety profile and antitumour activity in extensive-stage...
WCLC 2026: Phase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant NSCLC
WCLC 2026: Phase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan significantly improves progression...
WCLC 2026: Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer
WCLC 2026: Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate...
WCLC 2026: Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer
WCLC 2026: Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small...
WCLC 2026: Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC
WCLC 2026: Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC
WCLC 2026: Perioperative atezolizumab plus chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC
WCLC 2026: Perioperative atezolizumab plus chemotherapy more than doubles event-free survival in resectable stage...
WCLC 2026: Pumitamig plus elfetabart drozuntecan shows encouraging early activity in small cell lung cancer
WCLC 2026: Pumitamig plus elfetabart drozuntecan shows encouraging early activity in small cell lung cancer
WCLC 2026: Late-breaking HARMONi-2 analysis shows ivonescimab significantly improves overall survival versus pembrolizumab in PD-L1-Positive Advanced NSCLC
WCLC 2026: Late-breaking HARMONi-2 analysis shows ivonescimab significantly improves overall survival versus...
WCLC 2026: Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC
WCLC 2026: Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation